PDCD1 and cancer: The FDA has approved monoclonal antibodies (mAb) for the treatment of cancer that block the immune checkpoints cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the programmed cell death protein 1 (PD-1), or one of its two natural ligands, PD-L1.